|Mr. Dror Ben-Asher||Co-Founder, Chairman & CEO||884.67k||N/A||1966|
|Mr. Micha Ben-Chorin||Chief Financial Officer||548.14k||N/A||1969|
|Mr. Gilead Raday MPhil, MSc||Chief Operating Officer||539.74k||N/A||1975|
|Mr. Adi Frish||Chief Corp. & Bus. Devel. Officer||519.65k||N/A||1970|
|Mr. Rick D. Scruggs||Chief Commercial Officer, Pres of RedHill Biopharma Inc. & Director||736.35k||N/A||1960|
|Dr. Mark L. Levitt M.D., Ph.D.||Chief Scientific Officer||N/A||N/A||N/A|
|Ms. Alexandra Okmian||Sr. Bus. Devel. & Investor Relations Mang.||N/A||N/A||N/A|
|Ms. Valerie Graceffa||VP of Sales||N/A||N/A||N/A|
|Mr. Rob Jackson||Sr. VP of Sales & Marketing||N/A||N/A||N/A|
|Ms. Michelle Snelling||VP of HR||N/A||N/A||N/A|
RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults. Its clinical late-stage investigational development programs include RHB-204, which is in Phase 3 study for pulmonary nontuberculous mycobacteria infections; opaganib (Yeliva), an SK2 selective inhibitor, which has completed Phase 2 study to treat patients with SARS-CoV-2 severe COVID-19 pneumonia, in Phase 2 study to treat advanced unresectable cholangiocarcinoma, and in investigator-sponsored Phase 2 study to treat prostate cancer; RHB-107, which is in Phase 2/3 study to treat outpatients infected with COVID-19 disease, and preclinical evaluation study to treat advanced unresectable cholangiocarcinoma, as well as has completed Phase 2 study to treat gastrointestinal and other solid tumors; RHB-104, which is in Phase 3 studies for Crohn's disease; RHB-102 (Bekinda) that is in Phase 3 studies for acute gastroenteritis and gastritis, and has completed Phase 2 studies for irritable bowel syndrome with diarrhea; and RHB-106, an encapsulated formulation for bowel preparation, which is preparing for Phase 2/3 study. RedHill Biopharma Ltd. was incorporated in 2009 and is headquartered in Tel Aviv, Israel.
RedHill Biopharma Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.